T2807
胸苷磷酸化酶，重组 来源于大肠杆菌
recombinant, expressed in E. coli, buffered aqueous solution, ≥500 units/mL
别名:
胸苷：正磷酸脱氧-D-核糖基转移酶
重组
expressed in E. coli
质量水平
表单
buffered aqueous solution
浓度
≥500 units/mL
UniProt登记号
储存温度
2-8°C
基因信息
Escherichia coli K12 ... deoA(948901)
正在寻找类似产品? 访问 产品对比指南
一般描述
胸苷磷酸化酶抑制血管平滑肌细胞增殖。
应用
胸苷磷酸化酶已用于评估TAS-102治疗晚期实体瘤患者的研究。 胸苷磷酸化酶也已用于研究FP3蛋白对原发性结肠癌患者来源的肿瘤组织异种移植模型的抗肿瘤作用。
生化/生理作用
一种对胸腺嘧啶可逆性转化为胸腺嘧啶进行催化的酶。 胸苷磷酸化酶是嘧啶核苷挽救途径的一部分。
一种对胸腺嘧啶可逆性转化为胸腺嘧啶进行催化的酶。胸苷磷酸化酶是嘧啶核苷挽救途径的一部分。该途径允许嘧啶碱基被回收用于核苷酸生物合成，而1-磷酸戊糖被转化为磷酸戊糖分流和糖酵解的中间体。 大肠埃希菌胸苷磷酸化酶与人序列具有40%的序列同源性，已发现该序列与血管生成剂血小板衍生的内皮生长因子相同。 在鸡绒膜尿囊膜测定中，纯化的大肠埃希菌酶已显示出刺激血管生长的作用。
外形
溶于含2 mM尿嘧啶、0.02%叠氮化钠和牛血清白蛋白的0.5 M磷酸钾溶液
制备说明
从大肠埃希菌克隆并在过表达大肠埃希菌中产生
其他说明
一个单位将在25℃的pH 7.4下每分钟将1.0 μmole的胸苷和磷酸盐分别转化为胸腺嘧啶和2-脱氧核糖1-磷酸。
储存分类代码
12 - Non Combustible Liquids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
法规信息
常规特殊物品
含少量动物源组分生物产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Charlotte Gasson et al.
Journal of pharmaceutical and biomedical analysis, 72, 16-24 (2012-11-14)
Erythrocyte encapsulated thymidine phosphorylase (EE-TP) is under development as an enzyme replacement therapy for mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a fatal metabolic disorder resulting from an inherited deficiency of the enzyme thymidine phosphorylase. We report here the development and validation of
T Doi et al.
British journal of cancer, 107(3), 429-434 (2012-06-28)
TAS-102 consists of α, α, α-trifluorothymidine (TFT) and an inhibitor of thymidine phosphorylase (TPI). We conducted a dose-escalation phase I study in Japanese patients with advanced solid tumours. TAS-102 was administered twice daily on days 1-5 and days 8-12 in
Jian Zhang et al.
Cancer chemotherapy and pharmacology, 71(1), 103-113 (2012-10-12)
The difference between combinational and pre-planned sequential therapies using regimens that include non-anthracycline and taxane in the first-line setting remains unclear. The purpose of this study is to explore the interaction between vinorelbine (N) and capecitabine (X) in breast cancer
Domenico Ribatti et al.
Expert opinion on therapeutic targets, 16(12), 1215-1225 (2012-09-18)
Several anti-angiogenic agents have been developed and some of them have been clinically applied in the tumor therapy. Anti-angiogenic therapy faces some hurdles: inherent or acquired resistance, increased invasiveness, and lack of biomarkers. Characterization of tumor endothelial markers may help
Lian Lu et al.
Oncology reports, 28(4), 1332-1338 (2012-07-25)
Vascular endothelial growth factor (VEGF) is an important signaling protein and a predominant mediator of angiogenesis in tumor growth and metastasis. Therefore, antagonism of the VEGF pathway results in inhibition of abnormal angiogenesis, then suppression of tumor growth and metastasis.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持